![]() Duration of Adjuvant Chemotherapy for Stage III Colon Cancer: Final Results from the IDEA (International Duration Evaluation of Adjuvant chemotherapy) Collaboration. Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. Adrenal Gland as a Sanctuary Site for Immunotherapy in Patients with Microsatellite Instability-High Metastatic Colorectal Cancer. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. Microsatellite-Instability-High Advanced Colorectal Cancer. Pembrolizumab in Microsatellite Instability High Advanced Colorectal Cancer. Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. Fucà G, et al.,Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.KEYNOTE-177 Investigators.Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Gastroenterol Hepatol, 2022, 7, 4-6 ![]() Immune checkpoint inhibitors in colorectal cancer: dream and reality. Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study. ![]() A PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |